Elusys Therapeutics, Inc
Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Their mission is to accelerate the development and commercialization of novel biodefense solutions, such as their anthrax antitoxin ANTHIM®, for strategic government partners. They focus on developing antibody therapeutics for infectious diseases and have a strong partnership with government agencies to enhance biosecurity.
Industries
Nr. of Employees
small (1-50)
Elusys Therapeutics, Inc
Products
Monoclonal antibody anthrax antitoxin (obiltoxaximab)
A monoclonal antibody antitoxin developed to neutralize anthrax toxin; indicated for treatment of inhalational anthrax in combination with antibacterial drugs and for post-exposure prophylaxis when alternatives are unavailable or inappropriate.
Monoclonal antibody anthrax antitoxin (obiltoxaximab)
A monoclonal antibody antitoxin developed to neutralize anthrax toxin; indicated for treatment of inhalational anthrax in combination with antibacterial drugs and for post-exposure prophylaxis when alternatives are unavailable or inappropriate.
Services
Biodefense strategic advisory and regulatory consulting
Advisory services covering program strategy, regulatory pathway planning, and government contract navigation for organizations developing medical countermeasures.
Manufacturing process development and quality systems consulting
Consulting support for manufacturing scale-up, process validation, and implementation of quality management systems for biologic therapeutics.
Biodefense strategic advisory and regulatory consulting
Advisory services covering program strategy, regulatory pathway planning, and government contract navigation for organizations developing medical countermeasures.
Manufacturing process development and quality systems consulting
Consulting support for manufacturing scale-up, process validation, and implementation of quality management systems for biologic therapeutics.
Expertise Areas
- Monoclonal antibody therapeutics
- Biodefense medical countermeasures
- Clinical trial design and execution for infectious diseases
- Preclinical animal efficacy models
Key Technologies
- Monoclonal antibody production
- Intravenous single-dose formulation
- Lyophilized formulation development
- Preclinical infectious-disease challenge models